IBD risk of treatment with IL-17 antagonists

Trials in psoriasis, psoriatic arthritis, and ankylosing spondylitis have reported cases of inflammatory bowel disease (IBD) during anti-IL-17 treatment. However, a recent systematic review and meta-analysis did not find an increased risk for development of IBD in patients treated with IL-17 antagonists [1].

Dr Wolfgang Eigner (deceased 10 March 2019, in memoriam) and colleagues (Medical University of Vienna, Austria) conducted a systematic review and meta-analysis evaluating IBD risk during treatment with secukinumab, ixekizumab, or brodalumab in patients with psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. Included were 66 published and unpublished studies between 2010 and 2018. Data of 14,390 patients exposed to anti-IL-17 treatment was evaluated during induction treatment; 11 incident cases of IBD (worst-case scenario) were identified. In the 19,380 patients who analysed for the entire treatment period, 33 new cases were diagnosed (worst-case scenario). In the meta-analysis, a pooled incidence rate of 0 events for the worst-case scenario and for all sub-analyses was found. Prospective trials evaluating this possible risk are therefore warranted, according to the researchers.

1. Eigner W, et al. ECCO 2019, DOP86.



Posted on 9 May 201917 May 2024